US insurance program's experience with a multigene assay for early-stage breast cancer

American Journal of Managed Care

Volumn 17, Issue 5, 2011, Pages

  Hornberger, John ^a   Chien, Rebecca ^a   Krebs, Katie ^a   Hochheiser, Louis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; SENSITIVITY ANALYSIS;

BREAST NEOPLASMS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MARKOV CHAINS; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 79960260135     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
2. National Cancer Institute: SEER cancer statistics review, 1975-2006: Breast. http://seer.cancer.gov/csr/1975-2006/
3. National Comprehensive Cancer Network: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer, V. 1.2010. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717, 2005
5. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
6. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324, 2005 (Pubitemid 40646936)
7. Klang SH, Hammerman A, Liebermann N, et al: Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13:381-387, 2010
8. Philips Z, Ginnelly L, Sculpher M, et al: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8:iii-iv, ix-xi, 1-158, 2004
9. Weinstein MC, O'Brien B, Hornberger J, et al: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6:9-17, 2003 (Pubitemid 36228345)
10. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
11. Oratz R, Paul D, Cohn AL, et al: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3:182-186, 2007 (Pubitemid 351593669)
12. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
13. Simes RJ, Coates AS: Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146-152, 2001
14. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001 (Pubitemid 32565448)
15. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998 (Pubitemid 28135593)
16. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253-1258, 1996 (Pubitemid 26337709)
17. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
18. Hornberger J, Chien R: Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score in clinical practice. Presented at the 33rd San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr 20609)
19. Asad J, Jacobson AF, Estabrook A, et al: Does Oncotype DX recurrence score affect the management of patients with early stage breast cancer? Am J Surg 196:527-529, 2008
20. Henry LR, Stojadinovic A, Swain SM, et al: The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99:319-323, 2009
21. Thanasoulis T, Brown A, Frazier T: The role of Oncotype DX assay on appropriate treatment for estrogen positive, lymph node negative invasive breast cancer. Presented at the 2008 American Society of Breast Surgeons Annual Meeting, New York, NY, 2008
22. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
23. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
24. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
25. Brennan V, Wolowacz S: A systematic review of breast cancer utility weights. Presented at the 13th Annual International Meeting of ISPOR, Toronto, Ontario, Canada; May 3-7, 2009 (abstr PCN77)
26. Lindley C, Vasa S, Sawyer WT, et al: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16:1380-1387, 1998 (Pubitemid 28175755)
27. Zimmermann C, Baldo C, Molino A: Framing of outcome and probability of recurrence: breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios. Breast Cancer Res Treat 60:9-14, 2000 (Pubitemid 30307460)
28. Cole BF, Gelber RD, Gelber S, et al: Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358:277-286, 2001 (Pubitemid 32738966)
29. Briggs A, Claxton K, Sculpher M: Decision Modelling for Health Economic Evaluation. Oxford University Press, New York, NY, 2006
30. Schaapveld M, Visser O, Louwman M, et al: Risk of new primary nonbreast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol 26:1239-1246, 2008
31. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100:888-897, 2008 (Pubitemid 351881955)